Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Cash & Current Investments (2016 - 2026)

Heron Therapeutics filings provide 16 years of Cash & Current Investments readings, the most recent being $30.0 million for Q1 2026.

  • On a quarterly basis, Cash & Current Investments fell 15.85% to $30.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $30.0 million, a 15.85% decrease, with the full-year FY2025 number at $29.6 million, down 16.38% from a year prior.
  • Cash & Current Investments hit $30.0 million in Q1 2026 for Heron Therapeutics, up from $29.6 million in the prior quarter.
  • In the past five years, Cash & Current Investments ranged from a high of $121.7 million in Q3 2022 to a low of $29.3 million in Q3 2025.
  • Median Cash & Current Investments over the past 5 years was $40.6 million (2025), compared with a mean of $52.4 million.
  • Biggest five-year swings in Cash & Current Investments: plummeted 84.78% in 2022 and later surged 102.58% in 2024.
  • Heron Therapeutics' Cash & Current Investments stood at $71.0 million in 2022, then decreased by 19.66% to $57.0 million in 2023, then plummeted by 37.96% to $35.4 million in 2024, then fell by 16.38% to $29.6 million in 2025, then rose by 1.29% to $30.0 million in 2026.
  • The last three reported values for Cash & Current Investments were $30.0 million (Q1 2026), $29.6 million (Q4 2025), and $29.3 million (Q3 2025) per Business Quant data.